Sonoma Pharmaceuticals, Inc., a global healthcare leader developing and producing patented Microcyn technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, in partnership with EMC Pharma, LLC, announced they have entered into a co-marketing agreement to launch and sell an expanded prescription and OTC eye care product line.
The new eye care line will also feature refreshed design and improved packaging for Ocucyn Eyelid & Eyelash Cleanser.
The full line will be introduced at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024.
Sonoma and EMC Pharma entered into a distribution agreement in 2021, granting EMC Pharma the exclusive right to manage, market and distribute Sonoma's HOCl-based prescription dermatology and eye care products in the United States.
Pursuant to an addendum to this agreement, EMC Pharma will now additionally have the right to sell over-the-counter Ocucyn, and Sonoma will have the right to sell Acuicyn Eyelid & Eyelash Cleanser, a prescription product marketed to ophthalmologists.
In addition, Sonoma is introducing a new design and consumer-friendly packaging for Ocucyn, featuring a one-piece dispense mechanism, which allows for more convenient use.
Ocucyn and Acuicyn are hypochlorous acid-based solutions designed to gently cleanse the area surrounding the eye, removing dirt, oil and debris along with microorganisms such as bacteria, fungi and viruses, using the power of Microcyn technology.
The over-the-counter formulation of Ocucyn is ideal for daily eye hygiene and to relieve itch and irritation. Ocucyn is also used by ophthalmologists before and after eye exams, treatments or operations, or by skin care professionals following medspa treatments or any cosmetic procedure around the eyes.
Acuicyn provides a prescription strength formula that ophthalmologists can utilize in their practice or prescribe to their patients to manage symptoms of chronic eye conditions such as dry eye, contact lens intolerance, blepharitis and meibomian gland dysfunction.
The co-marketing of these products will allow Sonoma and EMC Pharma to provide their customers with additional options for eye care and expand the market reach for each product.
Acuicyn and the newly redesigned Ocuyn will be presented by Sonoma and EMC Pharma at the American Academy of Ophthalmology's annual meeting in Chicago, October 18-21, 2024.
"Eye care has been an area of growth for EMC and we are pleased to expand our partnership with Sonoma, and to expand our product offerings," said Eric Bailey, CEO of EMC Pharma. "Ocucyn will provide an over-the-counter option for our existing customers in addition to attracting new eye care customers in our distribution channels which include many government entities."
"Our partnership with EMC Pharma has been a success for both companies, and we are excited to open up new channels for both Sonoma and EMC with this co-marketing agreement. Both companies have invested in marketing eye care products and by coordinating our efforts, we expect to increase sales of both OTC and prescription eye care," commented Amy Trombly, CEO of Sonoma. "We look forward to presenting this expanded product line at the AAO conference in October."
Ocucyn is available to consumers through our website and on Amazon. Products with new packaging can be ordered now for October delivery.
For more information or to order Ocucyn Eyelid & Eyelash Cleanser, visit our website at https://otc.sonomapharma.com/products/ocucyn-eyelid-and-eyelash-cleanser or contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.